NTS-polyplex Nanoparticles for Targeted BDNF Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for Parkinson's disease, such as using viral vectors, face challenges in achieving targeted and controlled expression of neurotrophic factors like BDNF in dopaminergic neurons, leading to inadequate therapeutic effects and potential side effects due to excessive protein production and lack of specificity.
Innovation Solution
The development of NTS-polyplex, a biodegradable nanoparticle system that utilizes receptor-mediated endocytosis through the neurotensin type 1 receptor, allows for the targeted and controlled delivery of the BDNF gene to dopaminergic neurons using a biodegradable nanoparticle system composed of DNA, a caryophilic peptide, and a neurotensin carrier, ensuring specific expression under the control of the dopamine transporter promoter.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for gene therapy, then gene delivery is achieved, but targeting specificity and controlled expression are insufficient
Solution Approach 1:
The system segments the gene delivery mechanism into distinct functional components: the NTS-polyplex nanoparticle carrier for targeted delivery, the hDAT promoter for neuron-specific transcriptional control, and the BDNF coding sequence for therapeutic protein production. This segmentation allows each component to be optimized independently for its specific function, achieving both high targeting specificity and controlled expression.
Solution Approach 2:
The patent introduces the NTS-polyplex nanoparticle as an intermediary carrier that mediates between the BDNF gene and the target dopaminergic neurons. This intermediary enables controlled delivery by binding to neurotensin receptors on neuronal surfaces, facilitating endocytosis, and releasing the gene payload in a controlled manner, thereby improving targeting specificity compared to direct viral injection.
2Quantity of substance
If BDNF is overexpressed, then neurotrophic effect is enhanced, but excessive protein production causes side effects
Solution Approach 1:
The system implements local quality control through the hDAT promoter, which is specifically active only in dopaminergic neurons expressing the dopamine transporter. This ensures that BDNF is produced at therapeutic levels precisely where needed (in dopaminergic neurons) while preventing constitutive overexpression in other cell types that would cause harmful side effects. The promoter creates a spatially restricted expression pattern matching the disease pathology.
Solution Approach 2:
The patent changes the expression parameter from constitutive high-level expression (typical of viral vectors) to regulated expression driven by the hDAT promoter. This parameter change allows BDNF levels to be dynamically controlled based on the physiological needs of dopaminergic neurons, preventing excessive protein accumulation and associated side effects while maintaining sufficient neurotrophic support.
3Productivity
If viral vectors are used, then gene delivery is efficient, but biodegradability and safety are compromised
Solution Approach 1:
The patent replaces persistent viral vectors with biodegradable NTS-polyplex nanoparticles that perform their gene delivery function and then naturally degrade. These disposable nanoparticles are composed of biocompatible, biodegradable materials (poly-L-lysine, neurotensin, and plasmid DNA) that are metabolized and eliminated by the body, eliminating the long-term safety concerns and immunogenicity associated with viral vectors while maintaining efficient gene delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables prolonged and specific expression of BDNF in dopaminergic neurons, promoting neuronal survival, reinnervation, and restoration of dopamine levels, thereby reducing motor impairments in Parkinson's disease models, with minimal side effects.
Implementation Method 1
NTS-polyplex, a biodegradable nanoparticle system that utilizes receptor-mediated endocytosis through the neurotensin type 1 receptor
Implementation Method 2
Once in the endosome, the acid pH produced by the hydrogen pumps causes the PF to adopt an alpha-helix conformation, which alters the permeability of the endosomal membrane, enabling the NTS-polyplex to escape from endosome. In the cytoplasm, the plasmid DNA is guided into the cell nucleus by PK intervention
Data Source
Figure 1~4
Figure 3~9
Figure 5A~6B
AI summary
The present invention pertains to the field of genomics and nanotechnology, specifically to the in vivo gene expression technologies and their application in gene therapy. It consists of the performance of the NTS-polyplex nanocomplex, which can carry nucleic acids to the neurons, involving neurotrophic therapy to treat neurodegenerative diseases. In particular, the present invention addresses the treatment of Parkinson's disease by the regulated expression of the BDNF neurotrophin.